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Abstract
Background: Endoscopic mucosal resection (EMR) is currently the most used technique for resection of large distal
colorectal polyps. However, in large lesions EMR can often only be performed in a piecemeal fashion resulting
in relatively low radical (R0)-resection rates and high recurrence rates. Endoscopic submucosal dissection (ESD)
is a newer procedure that is more difficult resulting in a longer procedural time, but is promising due to the
high en-bloc resection rates and the very low recurrence rates. We aim to evaluate the (cost-)effectiveness
of ESD against EMR on both short (i.e. 6 months) and long-term (i.e. 36 months). We hypothesize that in the
short-run ESD is more time consuming resulting in higher healthcare costs, but is (cost-) effective on the
long-term due to lower patients burden, a higher number of R0-resections and lower recurrence rates with
less need for repeated procedures.
Methods: This is a multicenter randomized clinical trial in patients with a non-pedunculated polyp larger than
20 mm in the rectum, sigmoid, or descending colon suspected to be an adenoma by means of endoscopic
assessment. Primary endpoint is recurrence rate at follow-up colonoscopy at 6 months. Secondary endpoints
are R0-resection rate, perceived burden and quality of life, healthcare resources utilization and costs, surgical
referral rate, complication rate and recurrence rate at 36 months. Quality-adjusted-life-year (QALY) will be estimated
taking an area under the curve approach and using EQ-5D-indexes. Healthcare costs will be calculated by multiplying
used healthcare services with unit prices. The cost-effectiveness of ESD against EMR will be expressed as incremental
cost-effectiveness ratios (ICER) showing additional costs per recurrence free patient and as ICER showing additional
costs per QALY.
Discussion: If this trial confirms ESD to be favorable on the long-term, the burden of extra colonoscopies and
repeated procedures can be prevented for future patients.
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Background
Resection of colorectal adenomas has shown to lower
the mortality rate due to colorectal cancer with 60 % [1].
Especially large adenomas maintain a high risk of pro-
gression to invasive cancer, underlining the importance
of adequate resection [2]. Endoscopic resection of large
adenomas has been proven to be feasible and safe, with
less morbidity, mortality and costs compared to surgical
resection [3]. Endoscopic resection of non-pedunculated
adenomas is most often performed using the ‘lift-and-
cut’ endoscopic mucosal resection (EMR) technique [4].
However, in adenomas larger than 2 cm in size EMR can
often only be performed in a piecemeal fashion (pEMR)
due to the limited size of the snare, difficulty to position
the endoscope, and often extension of the polyp over
one or multiple folds [5, 6]. Although safe, piecemeal re-
section lowers the reliability of assessing the dysplasia
free resection margins (R0 resection) at histology. This is
also reflected by the relative high recurrence rate at
follow-up colonoscopy after EMR ranging between 12-
16 %, and even increasing up to 30 % in non-
pedunculated polyps exceeding 40 mm in size [7, 8].
For this reason endoscopic submucosal dissection
(ESD) was developed in Japan, a technique that enables
to achieve en-bloc resection even in large polyps [9].
Several retrospective observational studies compared
EMR and ESD. A recent meta-analysis pooled the results
yielding a total of 2299 lesions [10]. Although studies
were biased by baseline differences with special regard
to tumor location and polyp size due to lack of a ran-
domized design, results are promising. Rates of en bloc
resection and radical resection were much higher, and
the rate of recurrence was much lower in the ESD-
group (91.7, 80.3 and 0.9 % respectively) than in the
EMR-group (46.7, 42.3 and 12.2 % respectively). This
benefit comes at the expense of an about three-fold lon-
ger procedure time and more complications (perforation
rate 5.7 % versus 1.4 %). However, this safety profile may
be favorable in the distal colon, given the lower risk for
complications as compared to proximally located polyps
[11]. We hypothesize that the prolonged procedure time
will initially result in higher healthcare costs, but that
this time-investment will earn itself back on the long-
term due a higher number of R0-resections and lower
recurrence rates with less need for repeated procedures.
If indeed ESD proves to be (cost-)effective on the long-
term, burden of extra colonoscopies and repeated
procedures can be prevented for patients in the future.
It is important to address this gap in the current know-
ledge, especially now that screening programs have been
widely introduced and the detection of large adenomas
will further increase.
Therefore, the aim of this randomized clinical trial is
to evaluate the effectiveness and cost-effectiveness of
ESD against EMR on both short (i.e. 6 months) and
long-term (i.e. 36 months) for large (>20 mm) distal
non-pedunculated adenomas.
Methods
This randomized clinical trial will randomize between
ESD and EMR in patients with large distal non-
pedunculated colorectal adenomas. Seventeen Dutch
hospitals will participate, including three academic and
fourteen non-academic hospitals. The flowchart of the
design of the MATILDA-trial is displayed in Fig. 1.
Study population
The eligible study population consists of adult patients
with a non-pedunculated polyp larger than 20 mm in
the rectum, sigmoid, or descending colon found during
screening, surveillance or diagnostic colonoscopy
Inclusion criteria:
 non-pedunculated polyp larger than 20 mm in the
rectum, sigmoid or descending colon found during
colonoscopy
 indication for endoscopic treatment
 ≥18 years old
 Written informed consent
Exclusion criteria:
 suspicion of malignancy, as determined by
endoscopic findings (invasive Kudo pit pattern,
Hiroshima type C) [12, 13] or proven malignancy
at biopsy
 prior endoscopic resection attempt
 presence of synchronous distal advanced carcinoma
that requires surgical resection
 the risk exceeds the benefit of endoscopic treatment,
such as in patients with an extremely poor general
condition or a very short life expectancy
 the inability to provide informed consent
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Study setting
The endoscopists participating in this trial are selected
based on predefined criteria. With the knowledge that the
operational difficulty of colon ESD is very high, a mini-
mum prior number of procedures was defined in order to
avoid that results will be biased by a learning curve. Based
on the literature, 25 colorectal ESD-procedures is consid-
ered to be required to achieve expert experience [14–16].
Previous esophageal and stomach ESD experience alone
will not be enough to ensure colorectal ESD expertise, as
colorectal ESD is known to be technically more difficult
than upper gastro-intestinal ESD due to the more challen-
ging anatomical characteristics of the colon (thin wall,
folds, peristalsis, angulated positions, and fecal fluid) [17].
This study will therefore only allow endoscopists that have
performed >25 colorectal ESD procedures in the past
three years to treat patients randomized to the ESD arm.
In centers without ESD-experienced endoscopists, pa-
tients will be referred to an ESD-expert center when ran-
domized to the ESD-arm. Patients randomized to the
EMR arm will be treated by endoscopists which have
extensive experience with EMR, defined as >500 prior
EMR’s of which >50 in colorectal adenomas larger than
20 mm.
Recruitment and randomization
Initial recruitment of patients will be performed by
the local coordinating investigator of the participating
center. When a polyp is found at index colonoscopy
that fulfills the inclusion criteria, exclusion criteria
will be checked. In presence of exclusion criteria, this
will be registered in the screening log. In absence of
exclusion criteria, the local coordinating investigator
will provide oral and written information on the study
to the patient. Patients will have as much time as
they like to think about participation and will have
the chance to ask any questions on the study. There-
after the informed consent form is signed. In case of
non-participation, this will be recorded in the screen-
ing log (see Fig. 1). Independent computer-based
randomization will be performed (Castor Electronic
Data Capture (EDC), CIWIT b.v.) in a 1:1 ratio.
Fig. 1 Flowchart of the study design of the MATILDA-trial
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Randomization will be stratified by the size of the
polyp (20-30 mm, 31-40 mm, >40 mm), localization
(rectum, sigmoid, descending colon) and center using
block sizes of five per block. Due to the nature of the
treatment, neither patients nor endoscopists partici-
pating in this study will be blinded.
Outcome measures
A schedule of the study procedures with the outcome
measures is presented in Table 1.
Primary outcome
1. Recurrence rate at follow-up colonoscopy after
six months. This will be observed from resected
residual disease or, if not present, from biopsies of
the post-polypectomy scar [18].
Secondary outcomes
1. Radical (R0-)resection rate. This is defined as
dysplasia free vertical and lateral resection margins
at histology.
2. Perceived burden and quality-of-life (QoL) among
patients at 36 months. This will be assessed using
questionnaires. A summary of the investigated
domain and type of questions can be found in
Table 2. In short, colorectal cancer anxiety is
measured at baseline, 4 days and 4 weeks after ESD/
EMR, and after the 6 and 36 months follow-up
colonoscopy using an instrument originally
designed and validated in breast cancer patients,
and subsequently used to evaluate patients’
perception of colorectal cancer risk [19, 20].
Burden of the procedure will be measured on
day 4 after ESD/EMR and after the 6 months
follow-up colonoscopy using an instrument
proven to be a reliable and valid assessment
in prior studies [21–23]. Functional complaints
will be measured at baseline, 4 weeks after
ESD/EMR, and after the 36 months follow-up
colonoscopy using the Colorectal Function
Outcome (COREFO) instrument [24]. Quality-
of-life will be measured at baseline, 4 days and 4 weeks
after EMR/ESD, after the 6 months follow-up
colonoscopy, 13 months after EMR/ESD, and after
Table 1 Schedule of the study procedures
COREFO Colorectal Function Outcome, CRC colorectal cancer, D days, EMR endoscopic mucosal resection, EQ-5D-5 L EuroQol-5 dimensions-5 levels, ESD endoscopic
submucosal dissection, HCR health care resources, QoL quality of life, M months, W weeks; * only performed when recurrence is found at the 6 month
colonoscopy; ** only be performed when recurrence is found at the 6 and 12 month colonoscopy; *** only performed when recurrence is found at the
6 and 12 and 18 month colonoscopy
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the 36 months follow-up colonoscopy using the
EQ-5D-5L-instrument [25]. The EQ-5D, developed by
the EuroQol group, will be used to calculate quality
adjusted live years (QALYs) and consists of two parts,
the EQ-5D descriptive system and the EQ visual
analogue scale (EQ-VAS). The EQ-VAS records the
participant’s self-reported health on a VAS from 0
(labeled “worst imaginable health state”) to 100
(labeled “best imaginable health state”). The
EQ-5D descriptive system consists of five domains
(i.e. mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) and five
functioning levels (i.e. no problems, slight
problems, moderate problems, severe problems
or unable to function). The questionnaires will
be send digital to the participating patients by
Castor EDC (CIWIT b.v.). A reminder will be
send when participants don’t respond. Patients
who prefer to complete the forms on paper
will receive the questionnaires by mail.
3. Health resources utilizations and costs at
36 months. Data on healthcare utilization will
be gathered in the electronical case record form
for instruments used, time needed to perform the
procedure, admission to the ward and/or intensive
care, length of hospital stay, (repeated) treatment
or (prolonged) hospital stay for complications,
used anesthesia and anesthesia staff, material and
time needed for repeated treatment or
(prolonged) hospital stay for recurrence and
surgical referral. These data will be used to
calculate healthcare costs.
4. Surgical referral rate at 36 months. This is defined as
the total number of patients that are referred for
surgical management.
5. Long-term recurrence rate at follow-up colonoscopy
after 36 months. This will be observed from resected
residual disease or, if not present, from biopsies of
the post-polypectomy scar.
6. Complication rate within 30 days after treatment.
Intraprocedural perforation is defined as the
condition in which the abdominal cavity is visible
from the colorectal lumen during the procedure
because of mural tissue defects, that requires
(1) (prolonged) admission or (2) surgery.
Intraprocedural bleeding is defined as bleeding that
occurs during the procedure that is not controlled
by electrocoagulation and/or hemoclipping, and
that requires (1) transfusion or (2) termination of
the endoscopic resection. Postprocedural bleeding
is defined as bleeding within 30 days after the
procedure resulting in (1) new presentation at the
hospital, (2) hospital admission, or (3) repeated
colonoscopy to obtain hemostasis. Postprocedural
perforation is defined as perforation within 30 days
after the procedure that is detected after completing
of the procedure during which perforation did not
occur, diagnosed by abdominal pain with focal
guarding and a rise in C-reactive protein and/or
fever (T >38.5 C) in combination with free air
in the peritoneal cavity at abdominal CT-scan.
Postprocedural serositis is defined as abdominal
pain with focal guarding and a rise in C-reactive
protein and/or fever (T >38.5 C) within 30 days
Table 2 Patients’ perceived burden and quality of life assessment
Item N Method of measurement Scale
Patients’ perception of treatment Burden of the procedure 3 Verbal measure 5-point scale
Burden afterwards 3 Verbal measure 5-point scale
Overall perception 1 VAS 1-10
Patients’ perception of CRC risk CRC Risk Perception 3 1. VAS 1. 1-100
2. Verbal measure 2. 7-point scale
3. Comparative measure 3. 3-point scale
CRC Worry 2 Verbal measure 7-point scale
Colorectal Functional Outcome Incontinence 9 Frequency measure 5-point scale
Social impact 9 Frequency measure 5-point scale
Frequency 2 Frequency measure 5-point scale
Stool-related aspects 3 Frequency measure 5-point scale
Need for medication 3 Frequency measure 5-point scale
EQ-5D-5 L instrument Quality of life 5 Verbal measure 5-point scale
Overall health status 1 VAS 0-100
Abbreviations: CRC colorectal cancer, N number of questions per item, VAS Visual Analogue Scale
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after the procedure, but without signs of perforation
(free air at abdominal CT-scan) and in the




Dose and type of sedation to be given is at the discre-
tion of the endoscopist and will be registered. All colon-
oscopies will be performed with a high-resolution
magnifying video-endoscope. A colloidal solution (such
as succinylated gelatine) and dye will be used as the
injection fluid, mixture with 1:100.000 adrenaline is
optional. The purpose of this injection is to elevate the
lesion away from the muscle layer, and to accentuate the
plane of excision so that a wide and deep excision is
achieved. Marking of the periphery of the polyp with
coagulation is allowed to optimize the attempt of an en-
bloc or R0-resection. A snare is then passed through the
channel and opened around the lesion. The snare is
snugged around the lesion and pulled. Cautery is applied
to resect the lesion. Only when en-bloc resection is not
feasible, the endoscopist is allowed to perform the resec-
tion in a piecemeal fashion (pEMR) in as less pieces as
possible. The number of pieces will be registered. In case
of pEMR, adjunct therapy with either tipping with the
snare using forced coagulation (ERBE VIO 300; 25 W)
or treatment with argon plasma coagulation (ERBE VIO
300; 60 W, 2.0 L/min) will be performed. This will be
applied in short bursts to coagulate the entire edge of
the polypectomy site. Any remaining tissue in the poly-
pectomy site will also be coagulated. In case of en-bloc
EMR, adjunct therapy with coagulation will only be per-
formed when remnant tissue is suspected and must be
registered.
2. ESD-arm
Dose and type of sedation to be given is at the discre-
tion of the endoscopist and will be registered. All colon-
oscopies will be performed with a high-resolution
magnifying video-endoscope. A 0.9 % saline solution or
succinylated gelatine together with dye will be used as
the injection fluid. A circumferential incision will be
made using a ESD-knife. The incision must be placed on
a distance of 2-5 mm around the border of the polyp.
This is because thermal damage otherwise makes it diffi-
cult to evaluate the histological resection margins after
resection. A complete or partial circumferential incision
is performed first and then further dissection is per-
formed after the lesion is adequately situated. The
endoscopist is allowed to perform the resection using
the hybrid ESD (hESD) technique only as an escape
method. This hESD technique consists of a circular inci-
sion around the lesion, with partial preparation in the
submucosal layer that is sufficient to capture it with a
snare in a single piece. Adjunct therapy with either tip-
ping with the snare using forced coagulation (ERBE VIO
300; 25 W) or treatment with argon plasma coagulation
(ERBE VIO 300; 60 W, 2.0 L/min) will only be per-
formed when remnant tissue in suspected and must be
registered.
3. Both arms
For both procedures length of the procedure will be
measured, defined as the total time needed for resection
of the polyp, measured from the minute the injection
fluid is injected until the endoscopist finishes final in-
spection of the resection wound and all specimen pieces
are collected and removed.
For both procedures the opposite colonic wall of the
resection site will be marked with India ink in case the
adenoma is located in the sigmoid or descending colon,
to ensure that the post-polypectomy scar can be found
during follow-up.
For both procedures the following events are consid-
ered standard care, however, will be registered. In case
intraprocedural perforation occurs, this will be treated
using clips. In case of a minor bleeding from a small
vessel, contact coagulation with the tip of a knife or co-
agulation with hemostatic forceps will be used for
hemostasis. In cases of a severe bleeding from a large
vessel or artery, hemostatic forceps will be used for
hemostasis. If a pulsating large vessel is exposed within
the resection wound, clipping can optionally be used to
prevent delayed bleeding. If overnight admission is re-
quired, this will be registered including motivation.
Handling of the resected specimen
The resected specimen will be pinned on a paraffin, rub-
ber or cork sheet so that the mucous membrane sur-
rounding the lesion is evenly flattened and the mucous
membrane surface can be observed, unless fragmenta-
tion as a result of piecemeal resection hampers this. In
order to prevent autolysis after resection, the specimen
must be fixed as quick as possible. To prevent drying, it
will be soaked in a formalin solution. Thereafter, the
endoscopist is required to appropriately display the spe-
cimen so that the difference between the specimen and
the clinical images is minimized and the tumor margin
of the specimen can be judged. The endoscopists will
provide documentation (an explanatory text) to the
pathologist so that the basic information on preoperative
diagnosis, the site and morphology of the lesion, and the
tumor size can be accurately conveyed.
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Histopathological evaluation
The received specimen is fixed with a 4 % buffered for-
maldehyde solution for 24 h at room temperature. After
fixation, the specimen is photographed and inked. A tan-
gent that touches the focus closest to the horizontal
tumor margin is assumed. The first cut is carried out in
the direction perpendicular to the tangent. The speci-
men is sectioned into slices at intervals of 2 mm parallel
to the first cut. All slices are embedded in cassettes for
histological diagnosis. In case of long slices (>2 cm), the
slice is cut in half and both halves are embedded after
ink is applied at the cut edge.
Histological diagnosis of tumors is carried out in
accordance with the Vienna classification of gastrointes-
tinal neoplasia [26]. The histological type and resection
tumor margins in mm (horizontal and vertical) of the
lesion will be judged. Incomplete (R1) resection is
defined as dysplasia infiltration of the margins and/or if
infiltration cannot be determined because of coagulation
artefacts, as in piecemeal resection.
Follow-up colonoscopies
A follow-up colonoscopy is performed 6 and 36 months
after the procedure for all patients. The post-
polypectomy scar is checked for residual disease. In case
of macroscopic residual disease this is resected and send
for pathology. If not, three biopsies of the scar will be
taken. If no recurrence is found at the 6-months colon-
oscopy, the next colonoscopy will be planned at
36 months. Only if recurrence is found at the 6-months
colonoscopy, the next follow-up colonoscopy will be
planned 6 months later (T = 12 months). This is re-
peated until no recurrence is found with a maximum
of three endoscopic resection attempts before referral
to the surgeon. Length of the follow-up colonoscopies
will be registered for all time points, measured from
the introduction of the scope until the endoscopist
finishes final inspection of the postpolypectomy scar
(including taking biopsies and/or resection of residual
disease).
Safety monitoring
The investigators will inform the subjects and the
reviewing accredited medical ethics committee if any-
thing occurs, on the basis of which it appears that the
disadvantages of participation may be significantly
greater than was foreseen beforehand. The study will be
suspended pending further review by the accredited
medical ethics committee, except insofar as suspension
would jeopardize the subjects’ health. The investigators
will take care that all subjects are kept informed.
Adverse events (AE) are defined according to the com-
plication registration of the Dutch Society of Gastrointes-
tinal Diseases (NVMDL) for non-severe complications
[27]. Endoscopic resection related AE’s are: intraproce-
dural perforation, intraprocedural bleeding, postproce-
dural bleeding or postprocedural serositis that requires
(prolonged) admission <10 days and/or maximum 4 units
blood transfusion and/or endoscopic or percutaneous
(re-) intervention. Serious adverse events (SAE) are
defined as intraprocedural perforation, intraprocedural
bleeding, postprocedural bleeding or postprocedural
serositis or any other event with a possible or definite
causal relation with the study intervention as judged
by the treating physician that requires (1) > 10 days
(additional) admission and/or (2) 4 units blood trans-
fusion and/or (3) angiographic or surgical intervention
and/or, (4) ICU admission and/or (5) death. These SAE’s
will be reported to the accredited medical ethical commit-
tee of the University Medical Centre Utrecht (UMC
Utrecht), within 15 days after the local investigator has
first knowledge of the serious adverse events.
Quality control
Datamanagement of this study will be conducted by the
Netherlands Comprehensive Cancer Organisation (IKNL).
Quality of data entry will be ensured through the electro-
nical medical record, in which validation messages for
users are created. In this way, a message will be shown to
the data managers when something is incorrectly filled in
(for example: date in the past or future, unreliable low or
high patient age). Furthermore, the conduct of the
MATILDA-trial will be supervised through on-site moni-
toring. An initiation monitor visit will be planned for all
participating centers at the start of the inclusion
period. Second, every center will be visited by an
independent monitor after the first five included
patients, and will be checked on withdrawal of
informed consent, source data verification, whether
inclusion and exclusion criteria are correctly followed
and whether SAE’s are correctly reported. On-site
monitoring later in the trial will be done if necessary.
In this way, high quality will be ensured throughout
the study.
Study integrity
The medical ethical committee of the UMC Utrecht has
reviewed the study in accordance with the Dutch Med-
ical Research Involving Human Subjects Act (WMO)
and other applicable European regulations and has
granted a positive judgement. In addition, this study
protocol has been peer reviewed by external reviewers
from the Dutch Cancer Society (KWF Kankerbestrijding),
the funder of this trial.
Sample size calculation
The sample size is calculated for the primary outcome
parameter recurrence rate at 6 months. Sample size for
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recurrence rate is calculated based on the assumption
that the recurrence rate is 2 % in the ESD group and
12 % in the EMR group [8, 10, 16]. With a power of
80 % and a two-sided α of 0.05, the total number of
patients needed is 198. To correct for patients lost-to-
follow-up (7 %), a final total of 212 patients will be in-
cluded; 106 patients in each arm.
Data analysis
Primary analyses will be conducted on the intention-to-
treat principle. Normally distributed continuous vari-
ables will be expressed as mean (± standard deviation)
and not-normally distributed variables will be expressed
as median (interquartile range). Categorical data will be
presented with percentages. The outcome measures re-
currence rate, R0-resection rate, surgical referral rate,
and complication rate will be compared using a stratified
analysis with a test for binary outcomes. For the per-
ceived burden and quality of life analysis, data will be
collected, presented and compared according to the user
guides for the selected questionnaires [19, 24, 25, 28].
QALY estimates for the first 6-month follow-up period
(i.e. short-term) and the 36-month follow-up period (i.e.
long-term) will be calculated for both arms, using the
Dutch tariff and the self-reported EQ-indexes at the dif-
ferent contact moments [29]. An area under the curve
(AUC) approach will be followed by interpolating be-
tween the observations provided by the patients. Effects
will be discounted at 1.5 %, according to current Dutch
economic guidelines [30, 31]. QALY estimates will be
compared between both arms using non-parametric test
when not normally distributed. Healthcare costs will be
calculated by multiplying used healthcare services by the
appropriated unit cost prices. Own bottom-up micro
costing will be applied for ESD, EMR and colonoscopies.
For all other healthcare services reference prices will be
used, where available [30, 31]. Costs will be discounted
with 4 % according to current Dutch economic guide-
lines [30–32]. All costs will be expressed in 2018 euros.
The actual healthcare costs occurring in both arms will
be compared for the 6-month follow-up (i.e. short-term)
and the 36-month follow-up (i.e. long-term), respect-
ively. Costs estimates will be compared between both
arms using a non-parametric test. A p-value of < 0.05
will be considered significant.
Economic evaluation
In the economic evaluation, the balance between costs
and effects will be assessed between both arms on both
short (i.e. 6 months) and long-term (i.e. 36 months).
Results of both cost and effect measurement will be in-
tegrated and expressed as incremental cost-effectiveness
ratios (ICER) showing additional costs per recurrence
free patient and as ICER showing incremental costs per
incremental QALY. Both sensitivity and scenario ana-
lyses will be conducted. Sensitivity analysis will be con-
ducted for uncertain parameters, and scenario analysis
will be used to model for example the impact of antici-
pated changes of reduced frequency or prolonged inter-
val of follow-up colonoscopies after R0-resection.
Discussion
This will be the first randomized clinical trial comparing
ESD and EMR for large distal non-pedunculated polyps.
This study will not only provide information on the
effectiveness and safety of both treatment strategies, but
will also give insights in perceived patient burden, qual-
ity of life, the costs and cost-effectiveness of both treat-
ments. Given that all patients in this study will be
followed for a total duration of 36 months, we will be
able to evaluate both short-term (i.e. 6 months) as well
as long-term (i.e. 36-months) outcome measures.
We decided to include only patients with distal polyps
in this trial. Not only because we expect that the risk
profile for ESD will be more favorable in the rectum
compared to the right colon, but also because most ex-
perience with ESD in the Netherlands currently exists
with distal lesions [33]. We decided to include only non-
malignant neoplasia in this trial, as we think it is uneth-
ical to randomize patients with suspected T1 CRC to the
EMR arm. Given that EMR in polyps exceeding 20 mm
in size is most often performed in a piecemeal fashion,
inclusion of patients with suspected T1 CRCs in this
trial would undoubtedly result in unnecessary referral of
low risk T1 CRCs for surgery due to positive resection
margins [34].
With regard to the outcome measures, we chose to
evaluate the primary outcome measure recurrence rate
after a duration of 6 months. From literature, it is known
that about 76 % of recurrences after EMR occur after
3 months, increasing to 96 % after 6 months [35]. Thus,
6 months seems the moment we are able to catch the
vast majority of the recurrences. However, studies that
looked at long-term recurrence rates also found that re-
currence can occur up to 36 months after EMR [35–37].
Therefore, we feel a second outcome measure for long-
term follow-up is obligatory for this trial. R0-resection
was chosen as secondary outcome measure as this might
be an important factor to decide for the frequency and
interval of follow-up colonoscopies in future patients. If
our assumption is correct that a R0-resection does not
show recurrence at long-term follow-up, this will offer
an argument to prolong the interval and frequency of
follow-up colonoscopies after ESD with R0-resection.
Last, we decided only to apply a healthcare payer per-
spective when conducting the cost-effectiveness analysis.
Argument is that most of the patients will be above
65 years and thus retired, absence from work and/or
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lower efficiency while at work (i.e. productivity losses)
will be rare. Adding an additional questionnaire for
investing potential work losses from unpaid work were
considered too burdensome, and not pay off for the in-
creased risk of early termination.
In the development of the study design, sources of bias
were attempted to be minimized. Stratified randomization
will be performed in order to prevent confounding. More-
over, in order to pre-empt confounding due to differences
in operator experience between the groups, we decided
only to allow endoscopists with sufficient prior experience
to participate in this trial. Threshold values for participa-
tion were determined based on previous published litera-
ture and are defined in the study protocol [14–16]. Due to
the nature of the treatment, neither patients nor endosco-
pists participating in this study will be blinded. In order to
avoid information bias in the endoscopists’ evaluation of
recurrence, the study protocol mandates endoscopists to
take biopsies of the post-polypectomy scar. In this way, an
objective evaluation is guaranteed.
This study will support an optimal use of health re-
sources in the future and will have direct implications
for future patients with large colorectal polyps. Colorec-
tal cancer screening programs are expected to further
increase the detection rate of large colorectal lesions,
making it even more important to put effort in research
on the optimal resection technique.
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